DOE OSTI · 3365409
Process development and scale-up of value added molecules (CRADA Final Report)
Abstract
In this project, a genetically modified Saccharomyces cerevisiae was used to produce Histamine via fermentation of dextrose. Zymergen provided a tech transfer document based on their 1 L studies, where they observed a titer of 0.9 g/L with this strain. The ABPDU staff performed two bench scale campaigns, with four 2 L reactors in each campaign, to carry out tech transfer and process optimization studies. Optimization was pursued by varying initial glucose concentration, feed initiation conditions, feed strategies, vitamin supplementation, inoculum size, etc. We chose a 2 L process condition, with 4% inoculum volume, continuous feed initiated after complete ethanol depletion, that yielded the most promising titers (2.41 g/L) for scale up to 300 L.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Tanjore, Deepti [Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)]. 2026-05-27. Process development and scale-up of value added molecules (CRADA Final Report). https://doi.org/10.2172/3365409
Cite the original work for its findings. Save a collection to share your selection of sources.